🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🙌 hey #SABCS24, DO NOT MISS tomorrow’s poster spotlight 12, Fri 7-8:30am. #doubledoc Fabiana Napolitano will show her work on #chemokines in the #tumormicroenvironment and #endocrineresistance UTSW Simmons Cancer Center #spatialtranscriptomics

Cancer cells often become unresponsive to multiple types of therapy. It emerges that these ‘cross-resistant’ tumour cells release lipids that reprogram monocytes to stop them from activating tumour-targeting T cells go.nature.com/3BdF0BJ

Very greatful for the support of so many friends and collaborators! Amazing session this morning, so much data, so much work we can still do!

Giampaolo Bianchini describes the 🐘 in the room at #SABCS24. ❓Are PD-L1 and PD1 not created equal in breast? 🔑It is clear, neoadjuvant compared to adj immunotherapy should be given ⚠️ highlights ER low should be included in ICI trials #SABCS24 SABCS OncoAlert

Fabulous discussion by Giampaolo Bianchini on Gepardouze and CamRelief SABCS #SABCS24 OncoAlert

Super congratulations and grazie mille VIRGINIA KAKLAMANI Carlos L. Arteaga, M.D. Kate Lathrop & all that have made #SABCS24 a super unique and exciting event…really a can’t miss appointment for all involved in #BreastCancer care!💪👏🔝 OncoAlert SABCS Università di Genova Ospedale San Martino Genova

Very important and insightful review! Spatial biology will unravel the principles of tissue organisation! CaldasLab will focus on this space to understand how the different #breastcancer subtypes have prototypical TMEs. acrobat.adobe.com/id/urn:aaid:sc…

Patients treated by female physicians have better outcomes than those treated by men- our work led by Kiyan Heybati and Angela Jerath MD, MSc published today ➡️ bmchealthservres.biomedcentral.com/counter/pdf/10… Physician patient concordance associated with better outcomes particularly between female

🔥 Press Release🔥 Inavolisib/palbociclib and fulvestrant demonstrated a ‘statistically significant and clinically meaningful’ OS benefit in HR-positive HER2-negative ABC in the INAVO 120 study First drug targeting PIK3CA to demonstrate an OS ⬆️ in BC gene.com/media/press-re…

Over the last 30 years, the cancer death rate has fallen 34% as hundreds of new therapies and prevention strategies have been discovered and validated with NIH funding. Future progress depends on an unwavering national commitment to the lifesaving research supported by NIH.

The CheckPoints will once again be performing at the #AACR25 Annual Reception. Before this year's performance, learn more about the cancer researchers and oncologists who make up this cover band and what they can't wait to play in Chicago: brnw.ch/21wRodr #AACRBlog

Required reading for those interested in today's #AACR25 Discovery Science Plenary - Cancer Evolution: A Multifaceted Affair brnw.ch/21wSfay By @CirielloLab, Luca Magnani, and colleagues

Dr. Rakesh K. Jain honored with #AACR25 Lifetime Achievement in #CancerResearch for his pioneering contributions to understanding the TME. He shares that his first R01 was rejected 6 times. A great lesson in passion + persistence! Harvard University MassGeneral News AACR

"It is critically important that we raise our voices in support of innovative cancer science and medicine." AACR President Lillian L. Siu Patricia M. LoRusso, DO, PhD (hc), FAACR, calls on the #AACR25 delegates to stand together and call on Congress to make cancer research a national priority.

✅ KRAS G12V #PROTAC ✅ pan Ras inhibitor using cyclophilin A tricomplex 🎉extraordinary progress in targeting KRAS over the past 5 years. Still so much more to do, including ➡️overcoming resistance ➡️rational combinations ➡️mutant selective inhibitors of other residues 🍰

Excited to present the results of our study! If you have the chance, come and say hi! #AACR25 #breastcancer #PI3K

Many cancer patients are prescribed gabapentin for neuropathy symptoms. This finding of increased risk of dementia with gabapentin should be an important factor in use of this agent.

The pan-cancer proteome atlas, a mass spectrometry-based landscape for discovering tumor biology, biomarkers, and therapeutic targets dlvr.it/TLyB5j

✍️ Writing is thinking. 👉🏼A powerful editorial in Nature Reviews Bioengineering (Vol. 3, p. 431, 2025) reminds us of something timeless: in science, writing is far more than reporting results. It’s a way of sharpening thought. 👉🏼Even in an age shaped by large-language models,

The GIM12-TYPHER phase II trial is now out in The Oncologist! This study highlights the potential of trastuzumab + lapatinib as a chemo-free option for pretreated HER2+ metastatic breast cancer. 📖 doi.org/10.1093/oncolo… Congrats to all involved and to the GIM research network!